Naduparambil Korah Jacob
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naduparambil Korah Jacob has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
Alessandra M. Welker
13 shared publicationsChristine E. Beattie
13 shared publications- Cynthia M. Timmers
Incyte Corporation, Wilmington, USA
13 shared publications - Frederick F. Lang
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
13 shared publications J. Brad Elder
13 shared publicationsJihong Xu
13 shared publications
Latest Publications
- Open Access
- 14 May 2025
- Published by Taylor & Francis in International Journal of Radiation Biology
- p. 1-12
Addressing major issues regarding the roles of biodosimetry in responding to a major nuclear incident: report of EPR BioDose 2024 roundtable discussion
The roundtable discussion at EPR BioDose 2024 focused on identifying challenges for using biodosimetry in a large nuclear incident and exploring potential solutions to strengthen preparedness and response frameworks. This report outlines the major themes discussed, including advancements in techniques, challenges in scaling operations, and the future of biodosimetry in emergency response. Initiated by International Association of Biological and EPR Radiation Dosimetry (IABERD), a group of experts comprised of professionals in academia, government and other agencies, were asked to discuss the question: 'When and how should biodosimetry be used for an unplanned radiation explosion in the short or long term?' This question challenged participants to consider a range of scenarios, from immediate triage in the aftermath of an incident to long-term health monitoring and risk assessment. Panelists acknowledged that, while biodosimetry plays a crucial role in rapidly assessing exposure levels to guide medical response, its practical implementation can vary based on scale, resources, and timing. They emphasized that in the short term, methods that provide quick, large-scale screening are important, whereas long-term strategies might include more detailed biological assessments to understand cumulative effects and potential health risks. Despite the difficulty of a one-size-fits-all approach, the insights gathered aimed to inform strategies that balance speed, accuracy, and sustainability in biodosimetry practices. Finally, panelists emphasized the need for better communication about preparedness with the general public and healthcare providers, and a more collaborative approach that also takes into account evaluating the practicality of various methods for triage or guiding treatment.
- 14 May 2025
- Published by Taylor & Francis in International Journal of Radiation Biology
- p. 1-12
Open AccessAddressing major issues regarding the roles of biodosimetry in responding to a major nuclear incident: report of EPR BioDose 2024 roundtable discussion
The roundtable discussion at EPR BioDose 2024 focused on identifying challenges for using biodosimetry in a large nuclear incident and exploring potential solutions to strengthen preparedness and response frameworks. This report outlines the major themes discussed, including advancements in techniques, challenges in scaling operations, and the future of biodosimetry in emergency response. Initiated by International Association of Biological and EPR Radiation Dosimetry (IABERD), a group of experts comprised of professionals in academia, government and other agencies, were asked to discuss the question: 'When and how should biodosimetry be used for an unplanned radiation explosion in the short or long term?' This question challenged participants to consider a range of scenarios, from immediate triage in the aftermath of an incident to long-term health monitoring and risk assessment. Panelists acknowledged that, while biodosimetry plays a crucial role in rapidly assessing exposure levels to guide medical response, its practical implementation can vary based on scale, resources, and timing. They emphasized that in the short term, methods that provide quick, large-scale screening are important, whereas long-term strategies might include more detailed biological assessments to understand cumulative effects and potential health risks. Despite the difficulty of a one-size-fits-all approach, the insights gathered aimed to inform strategies that balance speed, accuracy, and sustainability in biodosimetry practices. Finally, panelists emphasized the need for better communication about preparedness with the general public and healthcare providers, and a more collaborative approach that also takes into account evaluating the practicality of various methods for triage or guiding treatment.
- Open Access
- 27 March 2025
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 4 (4) , pgaf108
Raman investigation of in vivo radiation exposure on melanin in murine hair
Determining the effects of ionizing radiation from unintended exposure in a nuclear event requires the identification of relevant biomarkers and development of methods to retrospectively estimate the absorbed dose. Melanin, a biologically important natural pigment found in hair, shows promise as a biomarker to assess potential radiation exposure. We investigated Raman spectroscopy as a rapid and noninvasive technique to assess changes in melanin from the hair of C57BL/6 mice to gamma radiation between 0 and 4 Gy. Two excitation wavelengths (532 and 785 nm) were employed to probe the melanin response for changes with radiation exposure. Excitation wavelength-dependent variation in Raman features indicates resonance Raman effects, where a 785-nm excitation is more sensitive to the effects of gamma radiation. Melanin-specific Raman features were identified as potential biomarkers for gamma-radiation exposure and used to distinguish between irradiated and nonirradiated mice. Partial least square discriminant analysis models of exposure exhibited enhanced sensitivity to irradiation at 785 nm excitation and yielded a sensitivity of 88% and a specificity of 83%. Mice were classified with 100% sensitivity and specificity up to day 7 at a known time point. A decline in specificity and classification accuracy correlated with alterations in melanin's spectra after >7 days following irradiation. Regression models of the Raman spectrum determined the exposed dose with a precision of <1 Gy at a known exposure time point. This noninvasive approach offers promising applications in radiation biodosimetry and medical monitoring, providing retrospective detection of gamma-radiation exposure at clinically relevant doses.
- 27 March 2025
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 4 (4) , pgaf108
Open AccessRaman investigation of in vivo radiation exposure on melanin in murine hair
Determining the effects of ionizing radiation from unintended exposure in a nuclear event requires the identification of relevant biomarkers and development of methods to retrospectively estimate the absorbed dose. Melanin, a biologically important natural pigment found in hair, shows promise as a biomarker to assess potential radiation exposure. We investigated Raman spectroscopy as a rapid and noninvasive technique to assess changes in melanin from the hair of C57BL/6 mice to gamma radiation between 0 and 4 Gy. Two excitation wavelengths (532 and 785 nm) were employed to probe the melanin response for changes with radiation exposure. Excitation wavelength-dependent variation in Raman features indicates resonance Raman effects, where a 785-nm excitation is more sensitive to the effects of gamma radiation. Melanin-specific Raman features were identified as potential biomarkers for gamma-radiation exposure and used to distinguish between irradiated and nonirradiated mice. Partial least square discriminant analysis models of exposure exhibited enhanced sensitivity to irradiation at 785 nm excitation and yielded a sensitivity of 88% and a specificity of 83%. Mice were classified with 100% sensitivity and specificity up to day 7 at a known time point. A decline in specificity and classification accuracy correlated with alterations in melanin's spectra after >7 days following irradiation. Regression models of the Raman spectrum determined the exposed dose with a precision of <1 Gy at a known exposure time point. This noninvasive approach offers promising applications in radiation biodosimetry and medical monitoring, providing retrospective detection of gamma-radiation exposure at clinically relevant doses.
- Open Access
Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition
Triple-negative breast cancer (TNBC) is the most aggressive subtype with high metastasis and mortality rates. Given the lack of actionable targets such as ER and HER2, TNBC still remains an unmet therapeutic challenge. Despite harboring high CDK4/6 expression levels, the efficacy of CDK4/6 inhibition in TNBC has been limited due to the emergence of resistance. The resistance to CDK4/6 inhibition is mainly mediated by RB1 inactivation. Since our aim is to overcome resistance to CDK4/6 inhibition, in this study, we primarily used the cell lines that do not express RB1. Following a screening for activated receptor tyrosine kinases (RTKs) upon CDK4/6 inhibition, we identified the TAM (Tyro3, Axl, and MerTK) RTKs as a crucial therapeutic vulnerability in TNBC. We show that targeting the TAM receptors with a novel inhibitor, sitravatinib, significantly sensitizes TNBC to CDK4/6 inhibitors. Upon prolonged HER2 inhibitor treatment, HER2+ breast cancers suppress HER2 expression, physiologically transforming into TNBC-like cells. We further show that the combined treatment is highly effective against drug-resistant HER2+ breast cancer as well. Following quantitative proteomics and RNA-seq data analysis, we extended our study into the immunophenotyping of TNBC. Given the roles of the TAM receptors in promoting the creation of an immunosuppressive tumor microenvironment (TME), we further demonstrate that the combination of CDK4/6 inhibitor abemaciclib and sitravatinib modifies the immune landscape of TNBC to favor immune checkpoint blockade. Overall, our study offers a novel and highly effective combination therapy against TNBC and potentially treatment-resistant HER2+ breast cancer that can be rapidly moved to the clinic.
Open AccessTargeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition
Triple-negative breast cancer (TNBC) is the most aggressive subtype with high metastasis and mortality rates. Given the lack of actionable targets such as ER and HER2, TNBC still remains an unmet therapeutic challenge. Despite harboring high CDK4/6 expression levels, the efficacy of CDK4/6 inhibition in TNBC has been limited due to the emergence of resistance. The resistance to CDK4/6 inhibition is mainly mediated by RB1 inactivation. Since our aim is to overcome resistance to CDK4/6 inhibition, in this study, we primarily used the cell lines that do not express RB1. Following a screening for activated receptor tyrosine kinases (RTKs) upon CDK4/6 inhibition, we identified the TAM (Tyro3, Axl, and MerTK) RTKs as a crucial therapeutic vulnerability in TNBC. We show that targeting the TAM receptors with a novel inhibitor, sitravatinib, significantly sensitizes TNBC to CDK4/6 inhibitors. Upon prolonged HER2 inhibitor treatment, HER2+ breast cancers suppress HER2 expression, physiologically transforming into TNBC-like cells. We further show that the combined treatment is highly effective against drug-resistant HER2+ breast cancer as well. Following quantitative proteomics and RNA-seq data analysis, we extended our study into the immunophenotyping of TNBC. Given the roles of the TAM receptors in promoting the creation of an immunosuppressive tumor microenvironment (TME), we further demonstrate that the combination of CDK4/6 inhibitor abemaciclib and sitravatinib modifies the immune landscape of TNBC to favor immune checkpoint blockade. Overall, our study offers a novel and highly effective combination therapy against TNBC and potentially treatment-resistant HER2+ breast cancer that can be rapidly moved to the clinic.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
Supplementary Data from Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
Supplementary Data from Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
Supplementary Data from Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
Supplementary Data from Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
Over 50% of all patients with cancer are treated with radiotherapy. However, radiotherapy is often insufficient as a monotherapy and requires a nontoxic radiosensitizer. Squalene epoxidase (SQLE) controls cholesterol biosynthesis by converting squalene to 2,3-oxidosqualene. Given that SQLE is frequently overexpressed in human cancer, this study investigated the importance of SQLE in breast cancer and non–small cell lung cancer (NSCLC), two cancers often treated with radiotherapy. SQLE-positive IHC staining was observed in 68% of breast cancer and 56% of NSCLC specimens versus 15% and 25% in normal breast and lung tissue, respectively. Importantly, SQLE expression was an independent predictor of poor prognosis, and pharmacologic inhibition of SQLE enhanced breast and lung cancer cell radiosensitivity. In addition, SQLE inhibition enhanced sensitivity to PARP inhibition. Inhibition of SQLE interrupted homologous recombination by suppressing ataxia-telangiectasia mutated (ATM) activity via the translational upregulation of wild-type p53-induced phosphatase (WIP1), regardless of the p53 status. SQLE inhibition and subsequent squalene accumulation promoted this upregulation by triggering the endoplasmic reticulum (ER) stress response. Collectively, these results identify a novel tumor-specific radiosensitizer by revealing unrecognized cross-talk between squalene metabolites, ER stress, and the DNA damage response. Although SQLE inhibitors have been used as antifungal agents in the clinic, they have not yet been used as antitumor agents. Repurposing existing SQLE-inhibiting drugs may provide new cancer treatments.Significance:Squalene epoxidase inhibitors are novel tumor-specific radiosensitizers that promote ER stress and suppress homologous recombination, providing a new potential therapeutic approach to enhance radiotherapy efficacy.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy Efficacy
Over 50% of all patients with cancer are treated with radiotherapy. However, radiotherapy is often insufficient as a monotherapy and requires a nontoxic radiosensitizer. Squalene epoxidase (SQLE) controls cholesterol biosynthesis by converting squalene to 2,3-oxidosqualene. Given that SQLE is frequently overexpressed in human cancer, this study investigated the importance of SQLE in breast cancer and non–small cell lung cancer (NSCLC), two cancers often treated with radiotherapy. SQLE-positive IHC staining was observed in 68% of breast cancer and 56% of NSCLC specimens versus 15% and 25% in normal breast and lung tissue, respectively. Importantly, SQLE expression was an independent predictor of poor prognosis, and pharmacologic inhibition of SQLE enhanced breast and lung cancer cell radiosensitivity. In addition, SQLE inhibition enhanced sensitivity to PARP inhibition. Inhibition of SQLE interrupted homologous recombination by suppressing ataxia-telangiectasia mutated (ATM) activity via the translational upregulation of wild-type p53-induced phosphatase (WIP1), regardless of the p53 status. SQLE inhibition and subsequent squalene accumulation promoted this upregulation by triggering the endoplasmic reticulum (ER) stress response. Collectively, these results identify a novel tumor-specific radiosensitizer by revealing unrecognized cross-talk between squalene metabolites, ER stress, and the DNA damage response. Although SQLE inhibitors have been used as antifungal agents in the clinic, they have not yet been used as antitumor agents. Repurposing existing SQLE-inhibiting drugs may provide new cancer treatments.Significance:Squalene epoxidase inhibitors are novel tumor-specific radiosensitizers that promote ER stress and suppress homologous recombination, providing a new potential therapeutic approach to enhance radiotherapy efficacy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy